BioSpace News Archive

The global counterfeit drug detection device market is all set to show upward graph of revenues during the forecast period of 2019 to 2027.

The global aromatherapy market is pegged to capture handsome amount in the form of revenues during the forecast period of 2019 to 2029.

NovaBiotics Ltd, a privately held clinical stage company developing novel immune based therapies for life-threatening and life-limiting diseases, announces that Deborah O’Neil, Ph.D., Chief Executive Officer of NovaBiotics, delivered a presentation highlighting NovaBiotics’ novel peptide drug candidates at the Peptide Therapeutics Forum 2021 that took place August 19-20, 2021, in Basel, Switzerland.

United Therapeutics Corporation announced it will present data from a clinical trial studying Tyvaso DPI™ in patients with pulmonary arterial hypertension at the European Respiratory Society International Congress 2021, which will be held virtually from September 5-8, 2021.

NeuroVision Imaging Inc. announced it has received an additional investment from the Alzheimer’s Drug Discovery Foundation – the foundation’s second round of funding to NeuroVision this year – to hasten development of a novel blood-based lab test to provide detection and measurement of biomarkers for Alzheimer’s disease and other dementias before clinical onset.

ViewRay, Inc. announced that the clinical team at Amsterdam University Medical Centers has started offering “same-day ablative treatment” using MRIdian SMART for patients who are eligible for single fraction MRI-guided radiation therapy.

Ascentage Pharma, a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases, announced its 2021 interim results and released an update on the recent progress in clinical development, strategic partnerships, and preparation for commercialization.

Medtronic plc announced financial results for its first quarter of fiscal year 2022, which ended July 30, 2021.

NRx Pharmaceuticals, announced that it has completed its previously announced private placement for the purchase of 2,727,273 shares of common stock.

Immunocore Holdings Plc announces that regulators in the United States and European Union have each accepted applications for the approval of tebentafusp for the treatment of HLA-A*02:01-positive adult patients with metastatic uveal melanoma.